Arcutis Biotherapeutics, Inc. (ARQT) FinancialsARQTArcutis Biotherapeutics, Inc.

Evaluating the bottom line, Arcutis Biotherapeutics, Inc. maintains a gross margin of 91.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.65%, while the net margin is 11.56%. These profitability ratios, combined with a Return on Equity (ROE) of 15.86%, provide a clear picture of how effectively ARQT converts its operational activities into shareholder value.

In the context of the broader market, ARQT competes directly with industry leaders such as PBLS and ACAD. With a market capitalization of $3.66B, it holds a leading position in the sector. When comparing efficiency, ARQT's gross margin of 91.58% stands against PBLS's 100.00% and ACAD's 90.81%. Such benchmarking helps identify whether Arcutis Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Arcutis Biotherapeutics has shown strong financial performance with a revenue increase to $129.86 million in Q2 2026, up from $81.50 million in the same quarter last year. The company also reported a profit of $15.01 million, translating to $0.11 per share, indicating a strong recovery.